Search Result

Results for "

ovarian

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (3) ADC Antibody (2) ADC Cytotoxin (10) Akt (5) Aldehyde Dehydrogenase (ALDH) (3) Angiotensin Receptor (3) Angiotensin-converting Enzyme (ACE) (2) Antibiotic (7) Antibody-Drug Conjugates (ADCs) (5) Antifolate (1) Apoptosis (88) Aurora Kinase (4) Autophagy (13) Bacterial (10) Bcl-2 Family (4) BCL6 (1) Bcr-Abl (2) Biochemical Assay Reagents (4) BMI1 (1) Bradykinin Receptor (1) c-Fms (1) c-Kit (1) Calcium Channel (7) Carbonic Anhydrase (1) Caspase (3) CD3 (1) CDK (7) Ceramidase (1) CMV (2) Complement System (1) COX (5) Cuproptosis (1) CXCR (2) Cytochrome P450 (11) Deubiquitinase (1) Disulfidptosis (1) DNA Alkylator/Crosslinker (5) DNA/RNA Synthesis (3) Drug Metabolite (1) Drug-Linker Conjugates for ADC (4) E1/E2/E3 Enzyme (2) EGFR (3) Endogenous Metabolite (14) Epigenetic Reader Domain (3) ERK (4) Estrogen Receptor/ERR (7) FAK (4) FAP (1) Ferroptosis (8) FGFR (1) FLT3 (3) Fungal (4) FXR (1) GABA Receptor (1) Glucosylceramide Synthase (GCS) (1) GLUT (1) Glutaminase (5) GnRH Receptor (8) GSK-3 (1) HDAC (2) HIF/HIF Prolyl-Hydroxylase (2) Histone Acetyltransferase (1) Histone Demethylase (4) Histone Methyltransferase (5) HSP (1) HSV (2) IAP (4) IGF-1R (1) Indoleamine 2,3-Dioxygenase (IDO) (2) Influenza Virus (2) Integrin (1) Interleukin Related (4) Isotope-Labeled Compounds (9) JAK (1) Keap1-Nrf2 (2) Lactate Dehydrogenase (2) Ligands for Target Protein for PROTAC (1) LXR (1) Macrophage migration inhibitory factor (MIF) (1) MAGL (1) MDM-2/p53 (5) MEK (1) MicroRNA (2) Microtubule/Tubulin (5) MMP (2) Molecular Glues (1) Monoamine Oxidase (2) Na+/K+ ATPase (1) NAMPT (1) Necroptosis (2) NEKs (1) NF-κB (1) Notch (2) Nucleoside Antimetabolite/Analog (2) Oct3/4 (2) P-glycoprotein (2) P2X Receptor (2) PAK (1) Paraptosis (1) Parasite (1) PARP (12) PDI (1) Phosphatase (1) Phospholipase (1) PI3K (1) Polo-like Kinase (PLK) (1) Potassium Channel (4) PPAR (5) Progesterone Receptor (1) PROTACs (4) Proteasome (1) Pyroptosis (1) Raf (3) RAR/RXR (1) Ras (2) Reactive Oxygen Species (4) Reverse Transcriptase (3) RIP kinase (1) ROR (1) Salt-inducible Kinase (SIK) (3) SARS-CoV (2) Sirtuin (1) Sodium Channel (1) Src (2) STAT (4) Survivin (2) TAM Receptor (1) TGF-β Receptor (1) Thymidylate Synthase (1) TNF Receptor (2) Toll-like Receptor (TLR) (2) Topoisomerase (14) Transferrin Receptor (1) TRP Channel (5) Tyrosinase (1) VEGFR (2) Virus Protease (1) Wee1 (1) Wnt (2) YB-1 (1)
By Research Areas:	Cancer (269) Cardiovascular Disease (23) Endocrinology (23) Infection (19) Inflammation/Immunology (50) Metabolic Disease (21) Neurological Disease (18)
Click Chemistry:	Alkynes (3)
Oligonucleotides:	Phospholipids (1) Polymers (3) Cholesterol (1)

292

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Upifitamab 1 Publications Verification	ADC Antibody	Cancer
Upifitamab is an ADC Antibody (a naked antibody of upifitamab rilsodotin), which can be used for antibody-coupled agent (ADC) synthesis. Upifitamab rilsodotin is an ADC targeting NaPi2b and is used in ovarian cancer research, particularly in platinum-resistant recurrent ovarian cancer .

Kumatakenin 1 Publications Verification	Apoptosis	Cancer
Kumatakenin, a flavonoid that is isolated from cloves shows the effect of inducing apoptosis in ovarian cancer cells .

ABT-510 acetate	Apoptosis	Inflammation/Immunology Cancer
ABT-510 acetate is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 acetate also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 acetate can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

Cetrorelix SB-75	GnRH Receptor	Endocrinology
Cetrorelix is a potent gonadotrophin-releasing hormone (GnRH) antagonist. Cetrorelix inhibits the endogenous luteinizing hormone surge during ovarian stimulation. Cetrorelix reduces cyclophosphamide induced ovarian follicular destruction in mice .

N-Acetylgalactosaminyltransferase 14 GALNT14	Endogenous Metabolite	Cancer
N-Acetylgalactosaminyltransferase 14 (GALNT14) is a mucin-type glycosylating enzyme polypeptide that promotes the migration of ovarian cancer by modifying mucin 13 (MUC13). GALNT14 can regulate the O-glycosylation and stability of MUC13, thereby mediating the malignant behavior of ovarian cancer cells .

Enloplatin	Others	Cancer
Enloplatin is a carboplatin analog, and can be used for study of ovarian cancer .

Chx-HT	Apoptosis	Cancer
Chx-HT has an anti-proliferation activity and promotes apoptosis on ovarian cancer cells .

IVHD-valtrate	Apoptosis	Cancer
IVHD-valtrate, an active Valeriana jatamansi derivative, is against human ovarian cancer cells in vitro and in vivo. IVHD-valtrate induces cancer cells apoptosis and arrests the ovarian cancer cells in the G2/M phase. IVHD-valtrate has the potential to be a novel chemotherapeutic agent for the human ovarian cancer research .

BO-0742	Others	Cancer
BO-0742, a derivative of AHMA and N-mustard, is a potent anti-cancer agent. BO-0742 significantly suppresses the growth of xenografts of human breast and ovarian cancers in mice .

PROTAC TG2 degrader-2	PROTACs Glutaminase	Cancer
PROTAC TG2 degrader-2 (compound 7) is a selective, competitive degrader targeting Transglutaminase 2 (TG2), with K_d > 100 μM. PROTAC TG2 degrader-2 inhibits the cell migration and decreases the level of TG2 in ovarian cancer cells. PROTAC TG2 degrader-2 can be used for ovarian cancer study .

RJF02215	MMP	Cancer
RJF02215 is an MMP-9 inhibitor. RJF02215 has growth-inhibitory activity on the ovarian cancer SKOV3 cell line. RJF02215 can be used for tumor research .

ABT-510	Apoptosis	Inflammation/Immunology Cancer
ABT-510 is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

(S)-SW IV-52 hydrochloride	Apoptosis	Cancer
(S)-SW IV-52 hydrochloride is a small molecule that can induce apoptosis in ovarian cancer. (S)-SW IV-52 hydrochloride has minimal single-agent activity at concentrations up to 200 μM .

FAK inhibitor 7	FAK Src Akt Autophagy	Cancer
FAK inhibitor 7 is a type of FAK inhibitor with an IC₅₀ value of 3.58 nM. FAK inhibitor 7 can inhibit the downstream signaling cascades of FAK (like Src and AKT), causing ovarian cancer cells to stall in the G0/G1 phase and induce cytotoxic autophagy. FAK inhibitor 7 can also suppress tumor metastasis and growth in ovarian cancer mice .

Guttiferone G	Sirtuin	Others
Guttiferone G inhibits recombinant human SIRT1 and SIRT2 (IC₅₀: 9 and 22 μM, respectively). Guttiferone G is weakly cytotoxic in A2780 human ovarian cell line (IC₅₀: 8.0 μg/mL). Guttiferone G can be isolated from Garcinia macrophylla .

DM-PIT-1 3,5-Dimethyl PIT-1	PI3K	Cancer
DM-PIT-1 is a PIP3/PH (phosphatidylinositol-3,4,5-triphosphate/Pleckstrin) interaction inhibitor . DM-PIT-1 has the potential for the research of ovarian cancer .

Solitomab AMG 110; MT110	CD3	Cancer
Solitomab (AMG 110) is a bispecific anti-CD3 and anti-epithelial-cell-adhesion-molecule (EpCAM) antibody. Solitomab can be used for the research of primary uterine and ovarian carcinosarcoma cancer .

MR22	Salt-inducible Kinase (SIK)	Cancer
MR22 is a potent pan-SIK (salt-inducible kinase) inhibitor. MR22 no longer exhibits activity on STE group kinases and displays excellent selectivity in a representative kinase panel. MR22-dependent SIK inhibition led to centrosome dissociation and subsequent cell-cycle arrest in ovarian cancer cells .

SMP-33693	Drug-Linker Conjugates for ADC	Cancer
SMP-33693 is a Drug-Linker Conjugate for ADC with a low payload shedding rate and has in vivo tumor inhibitory effects on ovarian cancer, gastric cancer, and breast cancer .

Eclalbasaponin IV	Others	Cancer
Eclalbasaponin IV is a triterpenoid that can be isolate from the aerial parts of Eclipta prostrata. Eclalbasaponin IV shows antitumor activity in human ovarian cancer cells .

SMP-93566	Drug-Linker Conjugates for ADC	Cancer
SMP-93566 is a kind of antibody-drug conjugates (ADCs) with a low payload shedding rate and has in vivo tumor inhibitory effects on ovarian cancer, gastric cancer, and breast cancer .

SIC-19	Salt-inducible Kinase (SIK)	Cancer
SIC-19 is a SIK2 inhibitor and promotes SIK2 protein degradation via the ubiquitination pathway. SIC-19 inhibits cancer cell growth and sensitizes cells to PARP inhibitors (Such as Olaparib (HY-10162)), as well as in ovarian cancer organoids and xenograft models .

Ganirelix acetate Ganirest	GnRH Receptor	Metabolic Disease
Ganirelix acetate (Ganirest) is an injectable competitive gonadotropin-releasing hormone (GnRH) antagonist. Ganirelix acetate directly competes against the endogenous molecule for receptor binding, and causes a rapid reduction in estradiol levels. Ganirelix acetate can be used for researching ovarian hyperstimulation syndrome (OHSS) .

SMP-88480	Drug-Linker Conjugates for ADC	Cancer
SMP-88480 is an Antibody-Drug Conjugates (ADCs). SMP-88480 is stable in mouse, monkey and human plasma and has in vivo tumor inhibitory effects on ovarian cancer, gastric cancer, and breast cancer .

LP-184	Others	Cancer
LP-184 (compound 6), an acylfulvene analog, inhibits tumor growth. LP-184 has potent anti-cancer activity in the ovarian, colon, prostate and pancreatic cell lines. (patent WO2007019308A2).

Imalumab BAX69; Anti-Human MIF Recombinant Antibody	Macrophage migration inhibitory factor (MIF)	Cancer
Imalumab (BAX69) is a recombinant, human IgG1 monoclonal antibody that targets macrophage inhibitory factor (MIF). Imalumab can be used for the research of ovarian carcinoma, recurrent malignant ascites and cancer .

11-Beta-hydroxyandrostenedione 4-Androsten-11β-ol-3,17-dione	Endogenous Metabolite 11β-HSD	Endocrinology
11-Beta-hydroxyandrostenedione (4-Androsten-11β-ol-3,17-dione) is a steroid mainly found in the the adrenal origin (11β-hydroxylase is present in adrenal tissue, but absent in ovarian tissue). 11-Beta-hydroxyandrostenedione is a 11β-hydroxysteroid dehydrogenase (11βHSD) isozymes inhibitor. As 4-androstenedione increases, measuring plasma 11-Beta-hydroxyandrostenedione can distinguish the adrenal or ovarian origin of hyperandrogenism .

RA-9	Deubiquitinase Apoptosis	Cancer
RA-9 is a potent and selective proteasome-associated deubiquitinating enzymes (DUBs) inhibitor with favorable toxicity profile and anticancer activity. RA-9 blocks ubiquitin-dependent protein degradation without impacting 20S proteasome proteolytic activity. RA-9 selectively induces onset of apoptosis in ovarian cancer cell lines and primary cultures derived from donors. RA-9 induces endoplasmic reticulum (ER)-stress responses in ovarian cancer cells .

BKM-570	Bradykinin Receptor	Cancer
BKM-570 is a nonpeptide bradykinin antagonist with anticancer effects. BKM-570 can be used in the study of lung cancer, prostate cancer and ovarian cancer .

Volvaltrate B	Biochemical Assay Reagents	Cancer
Volvaltrate B is an anticancer agent, iridoid, can be obtained from the root of valerian (Valeriana officinalis). Volvaltrate B is effective against ovarian tumors in female mice. Volvaltrate B has the potential to study cancer .

Nutlin-3a 40+ Cited Publications Rebemadlin	MDM-2/p53 E1/E2/E3 Enzyme Autophagy Apoptosis	Cancer
Nutlin-3a (Rebemadlin), an active enantiomer of Nutlin-3, is a potent murine double minute (MDM2) inhibitor (IC₅₀=90 nM). Nutlin-3a inhibits MDM2-p53?interactions and stabilizes the p53 protein, and induces cell autophagy and apoptosis. Nutlin-3a has the potential for the study of TP53?wild-type ovarian carcinomas .

Mirvetuximab M9346A	Antifolate	Cancer
Mirvetuximab (M9346A) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab is the antibody moiety of novel folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research .

Iproplatin CHIP	Others	Cardiovascular Disease Metabolic Disease Cancer
Iproplatin (CHIP) is an anti-cancer agent with reduced toxicity in testicular and ovarian cancers. The major reduced product of Iproplatin by glutathione is chloro-bis (isopropylamine) glutathionatoplatinum (II). Iproplatin is promising for research of Thrombocytopenia and a wide range of cancers .

OSU-ERb-12	Estrogen Receptor/ERR	Cancer
OSU-ERb-12 is a ERβ agonist, and suppress ovarian cancer cell proliferation in vitro and in vivo. OSU-ERb-12 decreases the expression of Snail .

Trastuzumab duocarmazine (vic)-Trastuzumab duocarmazine	Antibody-Drug Conjugates (ADCs)	Cancer
Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is a HER2-targeting ADC that is recognized and cleaved by histone B in tumor cells and selectively targets tumor cells. Trastuzumab duocarmazine has anti-tumor activity and can be used in cancer research related to uterine and ovarian sarcomas .

Calycosin 5+ Cited Publications Cyclosin	Apoptosis	Neurological Disease Cancer
Calycosin is a compound that can be isolated from Radix Astragali. Calycosin has strong antioxidant, anti-inflammatory and apoptosis-modulating effects. Calycosin can be used for the research of ovarian cancer and breast cancer .

NSC756093 SU093	Others	Cancer
NSC756093 is a potent inhibitor of the GBP1:PIM1 interaction. NSC756093 can potentially revert resistance to paclitaxel. NSC756093 can be used for ovarian cancer research .

Sulazepam	Others	Inflammation/Immunology
Sulazepam, a benzodiazepine, is a selective ovarian cancer G protein-coupled receptor (OGR1) agonist. Sulazepam has anticonvulsive action and has the potential for airway hyperresponsiveness (AHR) research .

Estrogen receptor antagonist 7	Estrogen Receptor/ERR	Cancer
Estrogen receptor antagonist 7 (compound 13) is a potent estrogen receptors (ER) antagonist. Estrogen receptor antagonist 7 has antiproliferative activity against breast and ovarian cancer cells. Anticancer and anti-uterotrophic activities .

TG53	Glutaminase Integrin FAK Src	Cancer
TG53 is a potent inhibitor of tissue transglutaminase (TG2) and fibronectin (FN) protein-protein interaction. TG53 inhibits formation of a complex with integrin β1 and activation of FAK and c-Src during SKOV3 cell attachment onto FN. TG53 can be used for ovarian cancer research .

Songorine	GABA Receptor	Cancer
Songorine is a diterpenoid alkaloid isolated from the genus Aconitum. Songorine is a GABAA receptor antagonist in rat brain and has anti cancer, antiarrhythmic and anti-inflammatory activities. Songorine has the potential for the treatment of Epithelial ovarian cancer (EOC) .

KIF18A-IN-13	Microtubule/Tubulin	Cancer
KIF18A-IN-13 (Compound 16) is an effective and orally active inhibitor of KIF18A with anticancer activity in vivo. KIF18A-IN-13 can be utilized for research in ovarian cancer .

MAGL-IN-1	MAGL	Cancer
MAGL-IN-1 is a potent, selective, reversible and competitive inhibitor of MAGL, with an IC₅₀ of 80 nM. MAGL-IN-1 exhibits anti-proliferative effects against human breast, colorectal, and ovarian cancer cells. MAGL-IN-1 blocks MAGL in cell-based as well as in vivo assays .

ZSQ836	Apoptosis CDK	Cancer
ZSQ836 is an orally active dual covalent inhibitor of CDK12/CDK13, with an EC₅₀ value of 32 nM against CDK12. ZSQ836 can induce apoptosis and exhibit anticancer activity in vivo. ZSQ836 can be used in the study of ovarian cancer .

SU056 1 Publications Verification	YB-1	Cancer
SU056 is a YB-1 inhibitor. SU056 induces cell-cycle arrest, apoptosis, and inhibits cell migration in ovarian cancer cells. SU056 interacts with YB-1 and inhibits and its associated downstream proteins and pathways. SU056 can enhance the cytotoxic effects of Paclitaxel (HY-B0015) .

Vesencumab MNRP-1685A	Complement System	Cancer
Vesencumab (MNRP-1685A) is IG1 antibody against neuropilin-1 (NRP-1). Vesencumab binds to NRP-1 and prevents the subsequent coupling of NRP-1 to VEGFR-2. Vesencumab has anti-angiogenic and anti-neoplastic activities. Vesencumab can be used in the research of metastatic solid tumors, including ovarian cancer .

Cat. No.	Product Name

HY-L173

Anti-Ovarian Cancer Compound Library

1,937 compounds

Ovarian cancer is the most common cause of death in female genital malignancies, with the highest mortality rate in female genital malignancies. It is characterized by difficulty in detection in the early stage of the disease, high recurrence rate and poor prognosis. In fact, ovarian cancer includes many pathologic types. It is usually divided into epithelial ovarian cancer, malignant germ cell tumors and sex cord stromal tumors, of which epithelial ovarian cancer is the most dominant form. Clinical treatment of ovarian cancer prioritizes surgery combined with paclitaxel chemotherapy. However, due to the spread and drug resistance of tumor cells, the recurrence of ovarian cancer is high. In this case, combined with traditional methods, the development of new therapeutic agents can help to improve the treatment effect of ovarian cancer.

MCE designs a unique collection of 1,937 compounds with definite or potential anti-ovarian cancer activity, which mainly targeting the main targets of ovarian cancer such as PARP, ATM/ATR, VEGFR and HIF/HIF Prolyl-Hydroxylase, etc. It is an essential tool for development and research of anti-ovarian compounds.

Cat. No.	Product Name	Type

HY-114491

Rineterkib

Fluorescent Dyes/Probes

Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF .

Cat. No.	Product Name	Type

HY-155902

Mal-PEG-OH (MW 5000) Maleimide-PEG-Hydroxy (MW 5000)	Drug Delivery
Mal-PEG-OH (MW 5000) can be used as a macroinitiator to obtain amphiphilic diblock copolymers by ring-opening polymerization of LA. Nanoparticles prepared using amphiphilic block copolymers can form active drug delivery systems. Nanoparticles encapsulate Triptolide (HY-32735), which can avoid the disadvantage of Triptolide’s poor water solubility and reduce its toxicity.

HY-155902A

Mal-PEG-OH (MW 2000) Maleimide-PEG-Hydroxy (MW 2000)	Drug Delivery
Mal-PEG-OH (MW 2000) can be used as a macroinitiator to obtain amphiphilic diblock copolymers by ring-opening polymerization of LA. Nanoparticles prepared using amphiphilic block copolymers can form active drug delivery systems. Nanoparticles encapsulate Triptolide (HY-32735), which can avoid the disadvantage of Triptolide’s poor water solubility and reduce its toxicity.

HY-155902B

Mal-PEG-OH (MW 1000) Maleimide-PEG-Hydroxy (MW 1000)	Drug Delivery
Mal-PEG-OH (MW 1000) was used as a macroinitiator to obtain amphiphilic diblock copolymers by ring-opening polymerization of LA. Nanoparticles prepared using amphiphilic block copolymers can form active drug delivery systems. Nanoparticles encapsulate Triptolide (HY-32735), which can avoid the disadvantage of Triptolide’s poor water solubility and reduce its toxicity.

Cat. No.	Product Name	Target	Research Area

HY-13545B

ABT-510 acetate	Apoptosis	Inflammation/Immunology Cancer
ABT-510 acetate is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 acetate also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 acetate can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

HY-13673A

Goserelin acetate ICI-118630 acetate	GnRH Receptor Apoptosis	Endocrinology Cancer
Goserelin acetate (ICI-118630 acetate), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin acetate can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer .

HY-P1103

CTCE-9908 1 Publications Verification	CXCR	Cancer
CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P4190

Fsh receptor-binding inhibitor fragment(bi-10)	GnRH Receptor	Endocrinology
FSH receptor-binding inhibitor fragment(bi-10) is a potent FSH antagonist. FSH receptor-binding inhibitor fragment(bi-10) blocks the binding of FSH to FSHR, and alteres FSH action at the receptor level. FSH receptor-binding inhibitor fragment(bi-10) results in the suppression of ovulation and causes follicular atresia of mice. FSH receptor-binding inhibitor fragment(bi-10) has the potential for utilizing to restrain the carcinogenesis of ovarian cancer by down-regulating overexpression of FSHR and ERβ in the ovaries .

HY-P0051

Lecirelin	GnRH Receptor	Endocrinology Cancer
Lecirelin, a synthetic gonadotropin-releasing hormone (GnRH) analogue, acts as a GnRH agonist. Lecirelin is widely used for the research of bovine ovarian follicular cysts .

HY-P5098

E(c(RGDfK))2	Peptides	Cancer
E(c(RGDfK)) is an αvβ3 integrin-specific binding moiety with tumor targeting properties. Increased uptake of E(c(RGDfK)) in human ovarian cancer OVCAR-3 xenograft tumors may be useful in cancer research .

HY-P0009

Cetrorelix SB-75	GnRH Receptor	Endocrinology
Cetrorelix is a potent gonadotrophin-releasing hormone (GnRH) antagonist. Cetrorelix inhibits the endogenous luteinizing hormone surge during ovarian stimulation. Cetrorelix reduces cyclophosphamide induced ovarian follicular destruction in mice .

HY-13545

ABT-510	Apoptosis	Inflammation/Immunology Cancer
ABT-510 is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

HY-13673

Goserelin ICI 118630	GnRH Receptor Apoptosis	Endocrinology Cancer
Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer .

HY-P1103A

CTCE-9908 TFA	CXCR	Cancer
CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P4144

Onvitrelin ucalontide Phor18-LHRH (338613)	GnRH Receptor	Endocrinology Cancer
Onvitrelin ucalontide ([Phor18-LHRH (338613)]) is an analogue of luteinizing hormone releasing hormone (LHRH) with antineoplastic activity. Onvitrelin ucalontide is a peptide with sequences of KFAKFAKKFAKFAKKFAKQHWSYGLRPG. Onvitrelin ucalontide effectively inhibits breast cancer, ovarian cancer and prostate cancer xenografts in mouse model .

HY-P4641

H-Trp-Phe-OH	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
H-Trp-Phe-OH is a dipeptide consisting of tryptophan and phenylalanine (Trp-Phe). H-Trp-Phe-OH is also an antihypertensive peptide with inhibitory activity on angiotensin-converting enzyme (ACE), dose-dependently increases NO levels, and decreases endothelin-1 (ET-1) levels. H-Trp-Phe-OH (2 mg/kg; subcutaneous injection; 6 injections over 3 days) causes an increase in ovarian weight in female mice .

HY-P4102

Cyclic PSAP peptide	Peptides	Cancer
Cyclic PSAP peptide is a cyclic pentapeptide (DWLPK). Cyclic PSAP peptide exhibits agent-like properties and could inhibit metastatic spread and restrain tumor development in general in vivo .

HY-P0205B

Saralasin TFA [Sar1,Ala8] Angiotensin II TFA	Angiotensin Receptor	Cardiovascular Disease Inflammation/Immunology
Saralasin ([Sar1,Ala8] Angiotensin II) TFA is an octapeptide analog of angiotensin II. Saralasin TFA is a competitive angiotensin II receptor antagonist with a K_i value of 0.32 nM for 74% of the binding sites, and has partial agonist activity as well. Saralasin TFA can be used for the research of renovascular hypertension, renin-dependent (angiotensinogenic) hypertension .

HY-P0205A

Saralasin acetate hydrate [Sar1,Ala8] Angiotensin II acetate hydrate	Angiotensin Receptor	Cardiovascular Disease Inflammation/Immunology
Saralasin ([Sar1,Ala8] Angiotensin II) acetate hydrate is an octapeptide analog of angiotensin II. Saralasin acetate hydrate is a competitive angiotensin II receptor antagonist with a K_i value of 0.32 nM for 74% of the binding sites, and has partial agonist activity as well. Saralasin acetate hydrate can be used for the research of renovascular hypertension, renin-dependent (angiotensinogenic) hypertension .

HY-P0205

Saralasin [Sar1,Ala8] Angiotensin II	Angiotensin Receptor	Cardiovascular Disease Inflammation/Immunology
Saralasin ([Sar1,Ala8] Angiotensin II) is an octapeptide analog of angiotensin II. Saralasin is a competitive angiotensin II receptor antagonist with a K_i value of 0.32 nM for 74% of the binding sites, and has partial agonist activity as well. Saralasin can be used for the research of renovascular hypertension, renin-dependent (angiotensinogenic) hypertension .

HY-P0037

Org-30850 Org 30850ANT	Peptides GnRH Receptor	Endocrinology
Org-30850 is a potent LHRH antagonist designed for treating hormone-dependent disorders. In animal studies, a single subcutaneous dose effectively inhibited ovulation in rats and significantly reduced testosterone levels in male rats for up to 48 hours post-administration. Daily doses of Org-30850 in female rats suppressed estrous cycles, decreased uterine and ovarian weights, and lowered estradiol and FSH serum levels. In male rats, prolonged treatment resulted in reversible reductions in gonadal function and testosterone levels, with almost complete recovery observed after cessation of treatment. Unlike comparable LHRH antagonists, Org-30850 exhibited minimal injection site irritation and no edematous reactions, suggesting a more favorable therapeutic profile .

HY-P2228

Chlamydocin	HDAC Apoptosis	Cancer
Chlamydocin, a fungal metabolite, is a highly potent HDAC inhibitor, with an IC₅₀ of 1.3 nM. Chlamydocin exhibits potent antiproliferative and anticancer activities. Chlamydocin induces apoptosis by activating caspase-3 .

Cat. No.	Product Name	Target	Research Area

HY-P99229

Upifitamab 1 Publications Verification	ADC Antibody	Cancer
Upifitamab is an ADC Antibody (a naked antibody of upifitamab rilsodotin), which can be used for antibody-coupled agent (ADC) synthesis. Upifitamab rilsodotin is an ADC targeting NaPi2b and is used in ovarian cancer research, particularly in platinum-resistant recurrent ovarian cancer .

HY-P99592

Solitomab AMG 110; MT110	CD3	Cancer
Solitomab (AMG 110) is a bispecific anti-CD3 and anti-epithelial-cell-adhesion-molecule (EpCAM) antibody. Solitomab can be used for the research of primary uterine and ovarian carcinosarcoma cancer .

HY-P99262

Imalumab BAX69; Anti-Human MIF Recombinant Antibody	Macrophage migration inhibitory factor (MIF)	Cancer
Imalumab (BAX69) is a recombinant, human IgG1 monoclonal antibody that targets macrophage inhibitory factor (MIF). Imalumab can be used for the research of ovarian carcinoma, recurrent malignant ascites and cancer .

HY-P99225

Mirvetuximab M9346A	Antifolate	Cancer
Mirvetuximab (M9346A) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab is the antibody moiety of novel folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research .

HY-P99547

Trastuzumab duocarmazine (vic)-Trastuzumab duocarmazine	Antibody-Drug Conjugates (ADCs)	Cancer
Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is a HER2-targeting ADC that is recognized and cleaved by histone B in tumor cells and selectively targets tumor cells. Trastuzumab duocarmazine has anti-tumor activity and can be used in cancer research related to uterine and ovarian sarcomas .

HY-P99179

CTX-2026	Inhibitory Antibodies	Cancer
CTX-2026 is a fully human antibody that binds to CD277. CTX-2026 shows an anti-tumor effect on ovarian tumor models. CTX-2026 can be used for the research of cancer .

HY-P99276

Abagovomab Anti-Human CA-125 Recombinant Antibody	Inhibitory Antibodies	Cancer
Abagovomab (Anti-Human CA-125 Recombinant Antibody) is a murine monoclonal anti-idiotypic antibody, against the tumor-associated antigen, CA-125. Abagovomab is generated by a mouse hybridoma, can imitate the human TAA, CA-125. Abagovomab can elicit humoral and cellular immune responses against ovarian cancer (oc) .

HY-P99386

Vesencumab MNRP-1685A	Complement System	Cancer
Vesencumab (MNRP-1685A) is IG1 antibody against neuropilin-1 (NRP-1). Vesencumab binds to NRP-1 and prevents the subsequent coupling of NRP-1 to VEGFR-2. Vesencumab has anti-angiogenic and anti-neoplastic activities. Vesencumab can be used in the research of metastatic solid tumors, including ovarian cancer .

HY-P99463

Batiraxcept AVB-S6-500	TAM Receptor	Cancer
Batiraxcept (AVB-S6-500) is a highly potent and specific AXL inhibitor, a recombinant fusion protein dimer containing the extracellular domain of human AXLM and human immunoglobulin G1 heavy chain (Fc). Batiraxcept binds to GAS6 and inhibits the interaction of GAS6 with AXL, thereby substantially reducing AXL signaled invasion and migration of highly metastatic cells in vitro and inhibiting metastatic disease in nonclinical models of aggressive human cancers. Batiraxcept is available for studies in advanced or metastatic clear cell renal cell carcinoma (ccRCC) and platinum sensitive recurrent ovarian cancer .

HY-P9943

Igovomab	Inhibitory Antibodies	Cancer
Igovomab is a monoclonal antibody for imaging. Igovomab can be used for ovarian cancer research .

HY-P99413

IMAB027 ASP1650	Inhibitory Antibodies	Cancer
IMAB027 (ASP1650) is a specific anti-CLDN6 mAb, while CLDN6 (Claudin 6) is a tight junction membrane protein, aberrantly expressed in various human cancer types, ovarian cancers particularly. IMAB 027 shows anti-tumor activity, and induces apoptosis in CLDN6 ⁺ ovarian and testicular cancer cell lines .

HY-P99667

Ipafricept 1 Publications Verification OMP-54F28; FZD8-Fc	Wnt	Cancer
Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine (HY-17026) in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer .

HY-P99506

Tamrintamab SC-003 mAb; SC-Mab003; SC34.28ss1	ADC Antibody	Cancer
Tamrintamab (SC-003 mAb, SC-Mab003, SC34.28ss1) is an ADC Antibody targeting to dipeptidase 3 (DPEP3 or MBD3). DPEP3 is a glycosyl phosphatidylinositol anchored metallopeptidase that is overexpressed in ovarian tumors. Tamrintamab can specifically bind DPEP3-expressing cells to produce cytotoxicity. Tamrintamab can be used in ovarian cancer research .

HY-P99377

Navicixizumab OMP-305B83; Anti-DLL4 Reference Antibody (navicixizumab)	Notch	Cancer
Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer .

HY-P99268

Seribantumab SAR 256212; MM 121; Anti-Human ERBB3/ErbB 3 Recombinant Antibody	EGFR Apoptosis	Cancer
Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets HER3. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models .

HY-P99672

Istiratumab MM 141; MM-005	IGF-1R EGFR	Cancer
Istiratumab (M-6495) is bispecific monoclonal antibody targeting IGF-1R and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers .

HY-P99593

Sofituzumab vedotin DMUC5754A	Antibody-Drug Conjugates (ADCs)	Cancer
Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer .

HY-P99593A

Sofituzumab vedotin (solution) DMUC5754A (solution)	Antibody-Drug Conjugates (ADCs)	Cancer
Sofituzumab vedotin (DMUC5754A) (solution) is an antibody-drug conjugate (ADC) that contains the humanized IgG1 anti-MUC16 monoclonal antibody and a potent anti-mitotic agent, monomethyl auristatin E (MMAE), linked through a protease-cleavable linker .

HY-P99396

Spesolimab BI 655130	Interleukin Related	Inflammation/Immunology
Spesolimab (BI 655130) is a mouse-derived humanized IgG1k antibody against IL-36R. IL-36 plays an important role in the immune system and Spesolimab is being investigated in palmoplantar pustulosis (PPP). Spesolimab was associated with a reduction in biomarkers associated with the innate, Th1/Th17 and neutrophil pathways .

HY-P99925

Enoticumab REGN421	Notch	Metabolic Disease Cancer
Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human Dll4. DLL4 is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively .

HY-P99605

Cinrebafusp alfa PRS 343	EGFR TNF Receptor	Cancer
Cinrebafusp alfa (PRS 343) is a high affinity CD137/HER2 bispecfic anticalin-based drug. Cinrebafusp alfa binds to recombinant human HER2 (K_d=0.3 nM) and human monomeric CD137 (4-1BB; K_d=5 nM). Cinrebafusp alfa facilitates T-cell costimulation by tumor-localized, HER2-dependent 4-1BB clustering and activation, further enhancing T-cell receptor-mediated activity and leading to tumor destruction. Cinrebafusp alfa has the potential for HER2+ solid tumors research .

Species:	Human (5) Mouse (1)
Tag:	His (5) Avi (1) Flag (1) Fc (1)
Source:	HEK293 (4) E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P7696

	CA125 Protein, Human (HEK293, His) rHuCA125, His; CA125 ovarian cancer antigen; CA125; CA125MUC-16	Human	HEK293
	CA125 is a giant mucin-like glycoprotein expressed by epithelial ovarian neoplasms and cells, which is an antigenic tumor marker. CA125 provides a protective, lubricating barrier against particles and infectious agents at mucosal surfaces. CA125 binds to mesothelin (MSLN) mediates heterotypic cell adhesion, contributing to the metastasis of ovarian cancer to the peritoneum by initiating cell attachment to the mesothelial epithelium. CA125 is widely used for monitoring with ovarian epithelial cancer. CA125 Protein, Human (HEK293, His) is a recombinant human cancer antigen 125 (CA125) with a His label and is expressed in HEK293 cells.

HY-P70296

	FOLR1 Protein, Human (HEK293, His) rHuFolate receptor alpha/FOLR1, His; Folate receptor alpha; FR-alpha; Adult folate-binding protein; FBP; Folate receptor 1; Folate receptor; ovarian tumor-associated antigen MOv18; FOLR1	Human	HEK293
	The FOLR1 protein is an important mediator of folate uptake, binding to folate and promoting the delivery of 5-methyltetrahydrofolate into cells. Studies show high affinity at neutral pH. FOLR1 Protein, Human (HEK293, His) is the recombinant human-derived FOLR1 protein, expressed by HEK293 , with C-His labeled tag.

HY-P72198

	FSHR Protein, Human (His) Follicle stimulating hormone receptor; Follicle stimulating hormone receptor isoform 1; Follicle-stimulating hormone receptor; Follitropin receptor; FSH receptor; FSH-R; Fshr; FSHR_HUMAN; FSHRO; LGR1; MGC141667; MGC141668; ODG1; ovarian dysgenesis 1	Human	E. coli
	FSHR, a G protein-coupled receptor, specifically recognizes follitropin (FSH) and activates PI3K-AKT and ERK1/ERK2 pathways by promoting cAMP production. Operating as a homotrimer, FSHR binds the heterodimeric FSH hormone, forming a functional unit for signal transduction. Its regulatory mechanisms involve interaction with ARRB2, and independently of FSH stimulation, it engages with APPL2, demonstrating versatility in diverse cellular contexts. FSHR Protein, Human (His) is the recombinant human-derived FSHR protein, expressed by E. coli , with N-6*His labeled tag.

HY-P70344

	FOLR1 Protein, Mouse (HEK293, His) rMuFolate receptor alpha/FOLR1, His; Adult folate-binding protein; FBP; folate binding protein; folate receptor 1 (adult); Folate receptor 1; folate receptor alpha; Folate receptor, adult; Folbp1; FOLR; FOLR1; FR-alpha; KB cells FBP; MOv18; ovarian tumor-associated antigen MOv18	Mouse	HEK293
	FOLR1 Protein, binding to folate and reduced folic acid derivatives, facilitates their delivery into cells. It maintains high affinity under neutral pH but undergoes a conformational change upon endocytosis, reducing affinity and releasing folates in slightly acidic pH. Crucial for embryonic development, cell proliferation, and renal folate reabsorption. FOLR1 Protein, Mouse (HEK293, His) is the recombinant mouse-derived FOLR1 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of FOLR1 Protein, Mouse (HEK293, His) is 208 a.a., with molecular weight of 33-37 kDa.

HY-P702884

	OTUD6B Protein, Human (His, FLAG) DUB; OTUD6B; ovarian tumor domain	Human	E. coli
	OTUD6B Protein, Human (His, FLAG) is the recombinant human-derived OTUD6B, expressed by E. coli , with N-His, Flag labeled tag. ,

HY-P72347

	CA125 Protein, Human (Biotinylated, HEK293, Fc-Avi) CA125 ovarian cancer antigen; CA-125; FLJ14303; MUC16	Human	HEK293
	The CA125 protein acts by binding to MSLN and plays a crucial role in forming a protective and lubricating barrier on mucosal surfaces. This interaction promotes heterotypic cell adhesion and is suggested to play an important role in peritoneal metastasis of ovarian cancer. CA125 Protein, Human (Biotinylated, HEK293, Fc-Avi) is the recombinant human-derived CA125 protein, expressed by HEK293 , with C-Avi, C-hFc labeled tag. The total length of CA125 Protein, Human (Biotinylated, HEK293, Fc-Avi) is 264 a.a., with molecular weight of 80-120 kDa.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81044

	MUC16 Antibody (YA890) MUC16; CA125; Mucin-16; MUC-16; ovarian cancer-related tumor marker CA125; CA-125; ovarian carcinoma antigen CA125	WB, ICC/IF, IHC-P, FC	Human
	MUC16 Antibody (YA890) is an unconjugated, approximately 1519 kDa, anti-MUC16 (YA890) monoclonal antibody. MUC16 Antibody (YA890) can be used for: WB, IF-Cell, IF-Tissue, IHC-P, FC expriments in human background without labeling.

HY-P81354

	Folate Binding Protein Antibody (YA1099) FOLR1; FOLR; Folate receptor alpha; FR-alpha; Adult folate-binding protein; FBP; Folate receptor 1; Folate receptor; adult; KB cells FBP; ovarian tumor-associated antigen MOv18	IHC-P	Human
	Folate Binding Protein Antibody (YA1099) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1099), targeting Folate Binding Protein. Folate Binding Protein Antibody (YA1099) can be used for IHC-P experiment in human background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-100433

PACMA 31		Alkynes
PACMA 31 is an irreversible, orally active protein disulfide isomerase (PDI) inhibitor with an IC₅₀ of 10 μM. PACMA 31 forms a covalent bond with the active site cysteines of PDI. PACMA 31 shows tumor targeting ability and significantly suppresses ovarian tumor growth without causing toxicity to normal tissues . PACMA 31 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-134061

Arecaidine propargyl ester hydrobromide		Alkynes
Arecaidine propargyl ester hydrobromide is an agonist of M2 muscarinic acetylcholine receptors and has the activity of inhibiting tumor cell proliferation. The application of arecaidine propargyl ester hydrobromide has shown that it can reduce the number of ovarian cancer cells in vitro and induce apoptosis and the production of reactive oxygen species (ROS) at specific concentrations. Arecaidine propargyl ester hydrobromide can also arrest cells at the G2/M phase of the cell cycle and increase the percentage of abnormal mitosis. Arecaidine propargyl ester hydrobromide is more sensitizing to ovarian surface epithelial cells with higher M2 receptor levels than to cancer cells. Arecaidine propargyl ester hydrobromide exhibits the effect of lowering arterial blood pressure when interacting with the cardiovascular system in a natural physiological state, indicating its potential pharmacological application .

HY-10822A

ONX 0801 trisodium BGC 945 trisodium; Idetrexed trisodium; CB 300945 trisodium		Alkynes
ONX 0801 (BGC 945) trisodium is a thymidylate synthase (TS) inhibitor, targeted to α-folate receptor–overexpressing tumors .

Cat. No.	Product Name		Classification

HY-N0171

Beta-Sitosterol (purity>80%) 5+ Cited Publications		Cholesterol
Beta-Sitosterol (purity>80%) includes β-sitosterol (≥80%), stigmasterol, campesterol and brassicasterol mainly. Beta-Sitosterol is a plant sterol. Beta-Sitosterol (purity>80%) interfere with multiple cell signaling pathways, including cell cycle, apoptosis, proliferation, survival, invasion, angiogenesis, metastasis and inflammation .

HY-W783254

C18 LPA PA(18:0e/0:0)		Phospholipids
C18 LPA (PA(18:0e/0:0)) is a water-soluble phospholipid that functions as a signaling molecule, influencing various cellular responses through G protein-coupled receptors (GPCRs). It is known to promote smooth muscle contraction, cytoskeletal rearrangement, and chemotaxis, while also playing a role in neurotransmitter release, cell proliferation, platelet aggregation, and Ca2+ mobilization. Elevated levels of C18 LPA in human plasma are associated with ovarian cancer and atherosclerosis, suggesting its potential as a biomarker for ovarian cancer.